Quince Therapeutics (QNCX) Intangibles (2022 - 2025)
Quince Therapeutics (QNCX) posted quarterly Intangibles of $67.8 million for Q4 2025, up 12.95% year-over-year from $60.0 million in Q4 2024, and little changed quarter-over-quarter from $67.7 million in Q3 2025.
Quince Therapeutics (QNCX) Intangibles (2022 - 2025) Analysis & Trends
Quince Therapeutics' Intangibles history runs 4 years deep, the most recent figure standing at $67.8 million for Q4 2025.
- In Q4 2025, Intangibles rose 12.95% year-over-year to $67.8 million; the TTM figure through Dec 2025 stood at $67.8 million (up 12.95% YoY), while the FY2025 annual figure was $67.8 million, up 12.95% from the prior year.
- Intangibles for Q4 2025 stood at $67.8 million, roughly flat from $67.7 million in the prior quarter.
- The five-year high for Intangibles was $67.8 million in Q4 2025, with the low at $5.9 million in Q2 2022.
- The 4-year median for Intangibles is $62.3 million (2024), against an average of $49.6 million.
- The sharpest annual moves came in 2023 and 2024: Intangibles surged 971.14% in 2023, then decreased 4.99% in 2024.
- Quince Therapeutics' Intangibles stood at $5.9 million in 2022, then soared by 971.14% to $63.2 million in 2023, then slipped by 4.99% to $60.0 million in 2024, then climbed by 12.95% to $67.8 million in 2025.
- Business Quant data shows QNCX's Intangibles at $67.8 million in Q4 2025, $67.7 million in Q3 2025, and $67.6 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 412.80 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.31 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 266.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 60.96 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 93.49 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Quince Therapeutics | 203.43 Mn | 203.43 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 67.82 Mn |
| Sep 30, 2025 | 67.73 Mn |
| Jun 30, 2025 | 67.57 Mn |
| Mar 31, 2025 | 62.37 Mn |
| Dec 31, 2024 | 60.05 Mn |
| Sep 30, 2024 | 64.53 Mn |
| Jun 30, 2024 | 61.79 Mn |
| Mar 31, 2024 | 62.25 Mn |
| Dec 31, 2023 | 63.20 Mn |
| Dec 31, 2022 | 5.90 Mn |
| Sep 30, 2022 | 5.90 Mn |
| Jun 30, 2022 | 5.90 Mn |